Weight-Loss Drugs Used in Nearly 1 in 10 UK Homes, Study Finds 2026

Dr. Lena Fischer
Weight-Loss Drugs Used in Nearly 1 in 10 UK Homes, Study Finds
This page may contain affiliate links.

Weight-loss drugs are now used in nearly one in 10 homes in Great Britain, according to a new study by Worldpanel by Numerator. The research found that 8.5% of households had at least one person taking GLP-1 medications in August, up from 6.3% in February.

This means there are more homes with weight-loss drug users than those containing vegetarians and pescatarians combined. The surge represents a significant shift in how Britons manage weight and has far-reaching implications for public health and the food industry.


Furniture with Meaning.

Find Original Home Decor sparking conversation at Grand Goldman Shop.


Sharp Rise in Weight-Loss Drug Use

About 2.6 million adults were using weight-loss medication in August, a rise of approximately 700,000 people since February. The increase is driven partly by the approval of weight-loss pills such as Wegovy in the UK in June, which previously required injections.

ADVERTISEMENT

Pills now account for more than one in 10 (11.2%) of GLP-1 users. Men are also driving the increase: they make up just under a third (32%) of people taking weight-loss medication, up from 23% in February. Male users have nearly doubled to 830,000, up from 440,000 nine months ago.

Impact on Grocery Spending

The increased use of medications such as Mounjaro and Wegovy is causing people to buy less food at the supermarket and change their buying habits. According to the survey of more than 9,600 households, in the year after starting the drugs, households with a GLP-1 user collectively spent £1bn less on groceries than expected compared with similar households.

In June, Worldpanel calculated the total saved by households with a GLP-1 user was £780m. This represents 415m fewer items bought, or £389 a year displaced per household. The data suggests that weight-loss drugs are not only changing waistlines but also shopping baskets.

Why This Matters

The rising use of weight-loss drugs has significant implications for public health, the pharmaceutical industry, and the food sector. As more people turn to these medications, demand for certain food products may decline, prompting supermarkets and manufacturers to adapt.

ADVERTISEMENT

Additionally, the shift toward pills and the growing number of male users indicate that weight-loss drugs are becoming more mainstream and accessible. This could lead to further changes in prescribing patterns and health policies.

  • 8.5% of UK households have at least one person using weight-loss drugs, up from 6.3% in February.
  • 2.6 million adults were using weight-loss medication in August, a rise of 700,000 since February.
  • Pills now account for 11.2% of GLP-1 users, following UK approval in June.
  • Men represent 32% of users, up from 23%, with male users nearly doubling to 830,000.
  • Households with a GLP-1 user spent £1bn less on groceries than expected in the year after starting the drugs.

What to Watch Next

As weight-loss drugs become more prevalent, we can expect continued scrutiny of their long-term effects and broader societal impacts. The food industry may need to innovate to cater to changing consumer preferences, while healthcare systems must adapt to the growing demand for these treatments.

For those considering weight-loss drugs, it's essential to understand that losing weight isn't enough—maintaining a healthy lifestyle is crucial. Ozempic and weight loss drugs: why losing weight isn't enough explores this balance in depth.

However, the rise of GLP-1 drugs also raises concerns about unapproved versions. Gray market weight-loss drugs: risks of unapproved retatrutide highlights the dangers of sourcing medications outside regulated channels.

ADVERTISEMENT

Interestingly, a recent study found that Ozempic weight loss is linked to less exercise, which could offset some benefits. This underscores the need for comprehensive approaches to weight management.

Comparing Household Usage and Spending

Metric February August Change
Households with GLP-1 user 6.3% 8.5% +2.2 percentage points
Adults using weight-loss medication 1.9 million (approx.) 2.6 million +700,000
Male users 440,000 830,000 +390,000
Share of male users 23% 32% +9 percentage points
Pill users (share of GLP-1 users) N/A 11.2% N/A
Grocery spending reduction (annual) £780 million (June estimate) £1 billion +£220 million

FAQ

How many people in the UK are using weight-loss drugs?

As of August, about 2.6 million adults in Great Britain were using weight-loss medication, according to the Worldpanel by Numerator survey. This represents 8.5% of households.

What impact do weight-loss drugs have on grocery spending?

Households with a GLP-1 user spent £1 billion less on groceries than expected in the year after starting the drugs. This equates to 415 million fewer items bought, or £389 saved per year per household.

Are weight-loss pills becoming more common?

Yes, pills now account for 11.2% of GLP-1 users, following the UK approval of weight-loss pills such as Wegovy in June. Previously, patients had to use injectable versions.

ADVERTISEMENT

Why are more men using weight-loss drugs?

The survey shows that men now make up 32% of users, up from 23% in February. Male users have nearly doubled to 830,000, indicating a broader acceptance and accessibility of these medications among men.

As the use of weight-loss drugs continues to grow, it's important to consider the broader implications for relationships and society. GLP-1s and relationships: how weight-loss drugs are changing dynamics is a topic worth exploring.

For those interested in the financial aspects, Retatrutide: Godzilla of weight-loss drugs and health benefits provides an overview of emerging treatments. Meanwhile, the push for subsidies in Australia is covered in PMOS weight loss drugs: Australia subsidy push for GLP-1.

Finally, if you're looking to combine medication with physical activity, strength and endurance training for weight loss: expert guide offers practical advice. And for a deeper look at how weight-loss drugs are reshaping relationships, see GLP-1 weight loss drugs: impact on relationships revealed.

ADVERTISEMENT
ADVERTISEMENT
Dr. Lena Fischer

Author

Dr. Lena Fischer

Dr. Lena Fischer is a board-certified physician and public health researcher focusing on preventive care, evidence-based medicine, and patient education for global audiences.


SPONSORED

Get Lifetime Access to the Lastest Movies, with Exclusive Offers & Free Express Order Delivery.

ADVERTISEMENT